Mobia Medical, Inc. is a commercial-stage medical device company focused on stroke recovery. The company develops and markets the Vivistim Paired VNS System, an FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. The therapy combines targeted vagus nerve stimulation with functional movement to promote neuroplasticity and drive improvements in motor function. Mobia Medical serves patients, providers, and care partners in the stroke care sector.

Summarised from the company's own disclosures

Industry Medical Devices Homepage ir.mobia.com
Sector Healthcare IR page ir.mobia.com
Tags
neurostimulation, stroke recovery, vagus nerve stimulation, implantable devices, motor impairment, Vivistim Paired VNS System
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 27
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026 Q2 2026 Q1 2026
Revenue 15.616M 13.505M 12.074M
Net profit -17.345M -21.043M -17.74M
Free cash flow -12.98M -17.21M -17.77M

Figure Q3 2026 Q2 2026 Q1 2026
Share price 9.45 13.4 —
P/FCF -6.07 -6.48 —

Filed figures

Figure Dec 2025
Balance sheet detail
Trade receivables (USD) 4.44M
Lease liabilities (USD) 1.31M
Cash and deposits (USD) 33.6M
Right-of-use assets (USD) 1.07M
Reported Jun 4, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Delivers revenue growth of 73% in the third quarter and raises full year 2026 revenue guidance

Austin, Texas, November 5, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today reported financial results for the quarter ended September 30, 2026.

Third Quarter 2026 and Recent Highlights

•Reported revenue of $15.6 million, representing 73% growth over the prior year period

•Achieved gross margin of 83.2%

•Increased average active territories in the quarter to 40, compared to 22.5 in the prior year period

•Announced inclusion of paired VNS in the updated 2026 AHA Guideline for stroke recovery

•Increased full year 2026 revenue guidance to be in the range of $57.0 million to $57.5 million compared to prior range of $54.0 million to $56.0 million

“This quarter, we delivered our strongest results yet. Revenue growth of 73% reflects the strength of our commercial execution and the predictable nature of our patient funnel,” said Richard Foust, President and Chief Executive Officer of Mobia Medical.

October 15, 2026

PDF Version

AUSTIN, Texas, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that the Company will report third quarter 2026 financial results on Thursday, November 5, 2026. Mobia Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Conference Call and Webcast Details

Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live and archived webcast can also be accessed via the News & Events page of the investor section of Mobia Medical’s website.

About Mobia Medical, Inc.

Mobia Medical, Inc. is a medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim® Paired VNS™ System is the first and only clinically validated, FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Therapy with the Vivistim® Paired VNS™ System combines targeted vagus nerve stimulation with functional movement to promote neuroplasticity and drive meaningful improvements in motor function. Mobia Medical is mobilizing patients, providers, and care partners to establish a better way forward in stroke care.

Investor Relations ContactLouisa Smith Gilmartin Group, LLC [email protected]

News & Events

Mobile sidebar dropdown Press Releases Events Presentations

Investor Contact

Louisa Smith Gilmartin Group, LLC [email protected]

Subscribe to our email alerts

August 28, 2026

PDF Version

AUSTIN, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that implantable paired Vagus Nerve Stimulation (VNS) has been recognized in the 2026 Guideline for Adult Stroke Rehabilitation and Recovery: A Guideline From the American Heart Association (AHA) and American Stroke Association (ASA), published August 27, 2026 in Stroke as a treatment option to improve upper-limb function and impairment for chronic stroke survivors.

The new guideline states that VNS paired with high-dose task-specific training may be considered to improve upper-limb function and impairment for eligible patients. Mobia Medical’s Vivistim® Paired VNS™ System is the only FDA-approved system that delivers this treatment approach.

“Recognition of paired VNS in the guideline for stroke recovery is a meaningful validation of the impact of our technology, which is grounded in our evidence-based approach to long-term stroke recovery,” said Richard Foust, President and Chief Executive Officer of Mobia Medical. “This is an important step in our mission to improve the standard of care for stroke survivors, and we're committed to continuing to build the evidence base that supports it.”

The updated AHA guideline supports several core principles of Mobia Medical’s approach to stroke recovery, including:

  • The importance of continuity of care with ongoing functional assessments for at least one year

  • The recognition of high-dose, task-specific therapy as a core component of effective stroke therapy

  • The evaluation of patient-specific functional outcomes concurrent with standardized measures of impairment and function

“It’s impactful to see paired VNS included in the new guideline. As a stroke neurologist, I've noticed that most of our advancements have focused on the hyperacute treatment of stroke, without many options for patients in the chronic phase with persistent motor deficits,” said David Z. Rose, M.D., Professor of Neurology, University of South Florida Morsani College of Medicine and Co-director of the Neurocardiac Program at Tampa General Hospital. “To offer an evidence-based technology like paired VNS that supports recovery during the chronic phase, even years later, has changed how we view the continuum of stroke care at our hospital and at many centers nationwide.”

Stroke remains one of the leading causes of long-term disability in the United States. With approximately 800,000 strokes occurring annually and roughly 10 million stroke survivors living in the country today, this represents a growing patient population as stroke survival rates improve due to advancements in acute intervention.1,2 However, upper-limb motor impairment is among the most common and disabling long-term consequences of stroke, and patients often plateau in their recovery around the onset of the chronic phase, or six months post-stroke. Treatment options to address these lasting deficits have historically been limited.

References

[1] Martin, Seth S., et al. "2025 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association." Circulation 151.8 (2025): e41-e660. [2] Waziry, Reem, et al. "Time Trends in Survival Following First Hemorrhagic or Ischemic Stroke Between 1991 and 2015 in the Rotterdam study." Stroke 51.3 (2020): 824-829.

About Mobia Medical, Inc.

Mobia Medical, Inc. is a medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim® Paired VNS™ System is the first and only clinically validated, FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Therapy with the Vivistim® Paired VNS™ System combines targeted vagus nerve stimulation with functional movement to promote neuroplasticity and drive meaningful improvements in motor function. Mobia Medical is mobilizing patients, providers, and care partners to establish a better way forward in stroke care.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the potential effect of the 2026 AHA and ASA guideline on clinical practice and on adoption of Vivistim Therapy, Mobia Medical's plans for continued clinical and real-world evidence generation, and Mobia Medical’s goal of changing the standard of care in stroke recovery. Forward-looking statements can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms. Mobia Medical cannot assure you that the forward-looking statements in this press release will prove to be accurate. Information in this press release may also include statements relating to past performance, which should not be regarded as a reliable indicator of future performance. Forward-looking statements are based on current expectations and assumptions together with projections of the future, which are inherently uncertain and involve risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied. These risks and uncertainties include, among others, those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in Mobia Medical’s filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release, and Mobia Medical undertakes no obligation to update or revise any forward-looking statements except as required under applicable law. Mobia Medical may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements. The 2026 AHA and ASA guideline addresses treatment approaches and does not endorse any product or manufacturer.

Investor Relations Contact

Louisa Smith Gilmartin Group, LLC [email protected]

Media Inquiries Contact

Terri Clevenger [email protected]

News & Events

Mobile sidebar dropdown Press Releases Events Presentations

Investor Contact

Louisa Smith Gilmartin Group, LLC [email protected]

Subscribe to our email alerts

Prompts

Mobia Medical, Inc. (ticker MOBI), listed in United States.

Company History

Date Change Detail
Mar 11, 2026 Renamed MicroTransponder, Inc. → Mobia Medical, Inc.

ETFs Holding Mobia Medical, Inc.

ETF Weight in ETF Shares Market value As of
MSSM 0.00% 2,893 $ 32.286K Aug 31, 2026